Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

AI-Assisted Medical Decision-Making

NCT06846229 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2025-02-24
Last updated
2025-03-03

Condition(s) studied

Real-world Study

Investigational drug(s) / intervention(s)

AI-associated strategy

AI-associated strategy: The intervention in this study involves an AI system that leverages multimodal data fusion to support the clinical decision-making and evaluation of diseases. Patients in this cohort will undergo standard examinations, with clinical decisions guided by the recommendations generated by the AI system.

Study summary

The study builds and applies an AI model to help doctors predict patient diagnoses and outcomes, such as survival or hospital stay. Real-time, multimodal data (labs, vital signs, history, imaging) from hospital records will be used. Patients will be tracked to compare the AI's performance with standard care. The goal is to improve diagnosis and treatment accuracy in a real-world, prospective study.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Patients admitted to any department of the hospital (e.g., ICU, general wards, emergency, outpatient services) during the study period. 2. Patients with available real-time electronic health record (EHR) data, including at least two of the following: laboratory results, vital signs, medical history, and imaging data. Exclusion Criteria: Patients currently enrolled in another clinical trial that could interfere with data collection or outcomes of this study.

Primary outcome measure(s)

  • Area Under the Curve (AUC) — 1 year
    AUC of the ROC curve, used to quantify diagnostic accuracy. No unit (a ratio or percentage, typically expressed as a number between 0 and 1).
  • Overall Hospital Resource Utilization Improvement — 1 year
    The percentage reduction in overall hospital resource use (e.g., bed days, ICU admissions, diagnostic tests) attributed to AI-assisted decision-making, expressed as a percentage.
  • Population-Level Diagnostic Accuracy Enhancement — 1 year
    The overall improvement in diagnostic accuracy across all hospital patients (e.g., percentage of correct diagnoses or reduction in misdiagnoses) facilitated by the AI model, expressed as a percentage or ratio.
  • System-Wide Reduction in Adverse Event Rates — 1 year
    The percentage reduction in major adverse events (e.g., mortality, severe complications, or prolonged stays) across all hospital patients due to AI-assisted decision-making, expressed as a percentage.

Trial sites (2)

FacilityCityRegionStatus
First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang Recruiting
Second Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06846229 on ClinicalTrials.gov ↗ ← All trials in China